Opinion

Video

Insights from the TROPION-Lung05 Trial at ASCO 2024

Author(s):

Jason Porter, MD

Jason Porter, MD, analyzes the TROPION-Lung05 trial investigating Dato-DXd in non-small cell lung cancer patients with brain metastases, emphasizing crucial insights from this pivotal study.

Video content above is prompted by the following questions:

  1. Discuss the data that was presented at the ASCO 2024 on intracranial overall response rate in the TROPION-Lung05 trial with Dato-DXd in patients with brain metastasis from NSCLC.
  2. What are your key takeaways from this study and how will this impact the treatment of patients with brain metastasis from NSCLC?
Related Videos
1 KOL is featured in this series.
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
1 KOL is featured in this series.
1 KOL is featured in this series.
Divya Gupta, MD
Divya Gupta, MD
Ticiana Leal, MD
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Related Content
NSCLC Thumbnail
December 20th 2024

Top 5 NSCLC Content for 2024

Maggie L. Shaw
Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data showing both setbacks in clinical trial results and advancements in screening recommendations for at-risk patients.
FDA approval. | Image Credit: Pawel - stock.adobe.com
December 19th 2024

Ensartinib Receives FDA Approval for ALK-Positive Locally Advanced or Metastatic NSCLC

Cameron Santoro
The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or metastatic non–small cell lung cancer (NSCLC) naive to ALK treatment.
Highlights from SLEEP 2024
December 18th 2024

ICYMI: Highlights From SLEEP 2024

Kyle Munz
Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.
Syringe and vials | Image credit: Aliaksandr Marko – stock.adobe.com
December 17th 2024

FDA Rejects Subcutaneous Amivantamab for NSCLC Over Manufacturing Concerns

Hayden E. Klein
Subcutaneous amivantamab joins a growing list of drugs receiving complete response letters due to manufacturing facility issues.
Lungs | image credit: istock photo
December 13th 2024

Updated Data Show Zongertinib Yields Responses in 71% With Previously Treated HER2-Mutated NSCLC

Mary Caffrey
The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.
ICYMI: Highlights From ACTRIMS 2024
December 12th 2024

ICYMI: Highlights From ACTRIMS 2024

Kyle Munz
Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo